Login to Your Account

PharmaFrontiers Gets $23M To Advance MS Compound

By Randall Osborne

Tuesday, April 18, 2006
Less than two months after disclosing its plan to sell $23 million in stock through a private placement to push along its Phase IIb trial with Tovaxin for multiple sclerosis, PharmaFrontiers Corp. has closed the deal and is planning a 1-for-10 reverse stock split that would let the firm apply for a Nasdaq listing. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription